Is Corbus Pharmaceuticals a Buy Now?

506

It’s been a little over a decade since Corbus Pharmaceuticals (NASDAQ: CRBP) picked up rights to a synthetic cannabinoid analog called lenabasum. Corbus scooped up those rights on the cheap thanks to the experimental drug’s previous failure to work as a pain reliever in a mid-stage study.

Corbus has lenabasum in a late-stage pivotal trial as an anti-inflammation drug for patients with severe autoimmune conditions. Success could lead to billions in annual sales, but Corbus Pharmaceuticals has been trading at a market cap of just $477 million.

Ga naar Bron